Member since: 2017
Organization: Rocky Mountain Diabetes Lab
This is a great machine with a fantastic test menu.
Application Area: Immunoassay analyzer
"The Immulite 2000 is a great analyzer. It is hard to beat the test menu for variety and usefulness. It is a proven platform that keeps running and running. We have been so happy with performance, and reliability. It just keeps pumping out results year after year. It is one of our oldest machines, but it still keeps chugging along. Maintenance is also easy; but monthly maintenance takes a while with getting all the tubing clean. Another bright spot is the tech support. In our area we have great field engineers who are very responsive and reliable. I have not often had to wait for more than 24 hours for someone to get to our facility. The one bad area is the sales support. They are not responsive, or reliable. "
Graves’ disease (GD) is an autoimmune disorder caused by the presence of thyroid stimulating immunoglobulins (TSI) that bind to the TSH receptor on the thyroid cells and stimulate the uncontrolled production of thyroid hormones. Detecting the presence of TSI in the blood is a powerful diagnostic tool for the differential diagnosis of GD.
TSI measurements are also used to monitor the response to GD therapy and prediction of remission or relapse, confirming Graves’ ophthalmopathy, and for predicting neonatal thyroid hyperthyroidism. Incorporating the TSI assay into existing diagnostic algorithms has been shown to reduce overall direct costs of GD diagnosis by up to 43%, with the net cost of avoiding misdiagnosis reduced by up to 85%.
The IMMULITE® 2000/2000 XPi TSI assay is the first automated and quantitative TSI assay available today. TSH receptor antibody (TRAb) assays detect both thyroid blocking and stimulating antibodies. However, blocking antibodies inhibit TSH stimulation of thyroid cells and lead to hypothyroidism. The IMMULITE 2000/2000 XPi TSI assay detects thyroid stimulating antibodies, the specific cause of GD pathology, with a clinical sensitivity and specificity of 98.6% and 98.5% respectively. With a 65-minute total assay time and ready-to-use, stable reagents, the use of this assay can make the differential diagnosis of GD faster and easier, allowing patients to be diagnosed and treated sooner.